Brian Adams Sells 6,371 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) insider Brian Adams sold 6,371 shares of the company’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $116.83, for a total transaction of $744,323.93. Following the sale, the insider directly owned 50,254 shares of the company’s stock, valued at $5,871,174.82. This represents a 11.25% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kymera Therapeutics Stock Up 0.1%

KYMR stock opened at $117.39 on Friday. Kymera Therapeutics, Inc. has a 12 month low of $42.22 and a 12 month high of $130.05. The firm has a market cap of $9.76 billion, a P/E ratio of -36.23 and a beta of 1.96. The company’s 50-day moving average price is $114.16 and its two-hundred day moving average price is $94.90.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.09. The company had revenue of $65.00 million during the quarter, compared to the consensus estimate of $32.78 million. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The firm’s quarterly revenue was up 465.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.95) EPS. Equities analysts predict that Kymera Therapeutics, Inc. will post -3.78 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Citigroup reiterated a “buy” rating on shares of Kymera Therapeutics in a research report on Thursday, August 6th. Loop Capital set a $97.00 target price on shares of Kymera Therapeutics in a research report on Monday, June 8th. Barclays boosted their target price on shares of Kymera Therapeutics from $133.00 to $139.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. B. Riley Financial increased their price target on Kymera Therapeutics from $117.00 to $155.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Finally, Guggenheim raised their price objective on Kymera Therapeutics from $135.00 to $170.00 and gave the company a “buy” rating in a report on Monday, August 31st. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Kymera Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $128.70.

Institutional Investors Weigh In On Kymera Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Smartleaf Asset Management LLC raised its stake in shares of Kymera Therapeutics by 382.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after acquiring an additional 424 shares during the last quarter. Larson Financial Group LLC grew its stake in shares of Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after purchasing an additional 349 shares during the last quarter. Osaic Holdings Inc. grew its stake in shares of Kymera Therapeutics by 18,050.0% in the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after purchasing an additional 1,083 shares during the last quarter. GAMMA Investing LLC increased its holdings in Kymera Therapeutics by 27.5% in the second quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock valued at $52,000 after purchasing an additional 98 shares during the period. Finally, Caitong International Asset Management Co. Ltd bought a new position in Kymera Therapeutics during the 4th quarter worth $63,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.